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C E L L  B I O L O G Y
Cell size is a determinant of stem cell potential  
during aging
Jette Lengefeld1,2*, Chia-Wei Cheng3†, Pema Maretich4†, Marguerite Blair3, Hannah Hagen3, 
Melanie R. McReynolds5,6, Emily Sullivan3, Kyra Majors3, Christina Roberts7, Joon Ho Kang3,8, 
Joachim D. Steiner7,9, Teemu P. Miettinen3,10, Scott R. Manalis3,11,12, Adam Antebi7, Sean 
J. Morrison13,14, Jacqueline A. Lees3, Laurie A. Boyer4,11, Ömer H. Yilmaz3, Angelika Amon1,4
Stem cells are remarkably small. Whether small size is important for stem cell function is unknown. We find that 
hematopoietic stem cells (HSCs) enlarge under conditions known to decrease stem cell function. This decreased 
fitness of large HSCs is due to reduced proliferation and was accompanied by altered metabolism. Preventing HSC 
enlargement or reducing large HSCs in size averts the loss of stem cell potential under conditions causing stem 
cell exhaustion. Last, we show that murine and human HSCs enlarge during aging. Preventing this age-dependent 
enlargement improves HSC function. We conclude that small cell size is important for stem cell function in vivo 
and propose that stem cell enlargement contributes to their functional decline during aging.
INTRODUCTION
Adult stem cells are critical for the maintenance of many tissues in 
our body. For example, hematopoietic stem cells (HSCs) build the 
blood system throughout life. Their magnificent ability to prolif-
erate and differentiate into the blood lineages is illustrated by the 
observation that a single HSC can repopulate the hematopoietic 
compartment of a lethally irradiated mouse when coinjected with 
radioprotective bone marrow (BM) (1).
As in almost every cell type, HSC division is coupled to cell 
growth. An increase in cell volume and mass through macromolec-
ular biosynthesis ensures that stem cells retain a constant size after 
division. Growth control is mediated by the mTOR (mammalian target 
of rapamycin)  pathway, which regulates macromolecule biosynthesis 
in response to amino acid availability and growth signals (2). Cell 
growth ultimately controls cell cycle progression. Cdk4/6–cyclin D 
complexes drive the decision of HSCs to exit the quiescent state and 
to divide. They promote cell cycle entry by inactivating the retino-
blastoma (Rb) protein. Rb inhibits the G1/S transition by repressing 
expression of genes required for S phase entry (3).
After damage and during aging, stem cell function declines. For 
example, old HSCs are less competitive in transplantation assays 
compare to younger ones (4). How stem cell fitness declines during 
aging is only beginning to be understood. In culture, mammalian 
cells undergo replicative senescence—an irreversible cell cycle arrest 
(5). With age, senescent cells accumulate in mice and humans (6–8). 
Whether processes leading to replicative senescence in cultured cells 
also mediate stem cell aging in vivo is not clear.
A key characteristic of senescent cells is their large size (9, 10). 
Recent work in budding yeast and cultured human cells has provided 
an explanation for this observation. Senescent cells are large because 
cell growth and division are only loosely coupled. If cell division is 
blocked by damage-induced cell cycle checkpoints, then macromol-
ecule biosynthesis continues to drive cell growth. As a consequence, 
cells increase in size without a corresponding increase in DNA con-
tent. Once the cell cycle arrest has been lifted, cells resume division 
at a larger size and decreased DNA:cytoplasm ratio (11, 12). It fol-
lows that the more divisions a cell undergoes, the more frequently 
it encounters cell cycle arrest–inducing damage. Hence, cell size 
increases and DNA:cytoplasm ratio decreases during replicative ag-
ing of yeast and cultured mammalian cells (9, 13–15). Cellular en-
largement affects cell physiology in vitro. Young cells manipulated 
to grow to a large size without a corresponding increase in DNA 
content exhibit a number of phenotypes observed in senescent 
cells—foremost, proliferation defects (12, 16). Whether large cell size 
is a cause of senescence and fitness loss during cellular aging in vivo 
is not known.
We show here that cell size affects the function of HSCs in vivo. 
Conditions known to induce stem cell dysfunction—DNA damage, 
cell cycle arrest, increased frequency of cell division, and aging—cause 
HSCs to increase in size. Preventing HSC enlargement by interfer-
ing with macromolecule biosynthesis or reducing their large size by 
accelerating progression through G1 prevents the loss of stem cell 
potential. We conclude that cell size is a critical determinant of stem 
cell potential and propose that stem cell enlargement contributes to 
the functional decline of HSCs during DNA damage and aging.
RESULTS
Large cell size contributes to radiation-induced loss of stem 
cell fitness
Previous studies showed that growing primary human cells to a large 
size in vitro decreases their proliferation potential (12). Whether 
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large cell size interferes with proliferation in vivo has not yet been 
determined. We chose HSCs to address this question because of 
their small size. To address whether large HSC size is associated 
with decreased fitness, we first asked whether an insult known to 
reduce HSC fitness and to induce senescence—DNA damage (17)—
also causes an increase in HSC size. To induce DNA damage, we 
sublethally irradiated young mice with 3 gray (Gy). After 2 weeks, 
we isolated live HSCs (Lin−, Sca1/Ly6+, CD117/cKit+, CD150/
Slamf1+, CD48/Slamf2−, and 7-ADD−; fig. S1A) and examined their 
size by Coulter counter and microscopy. With both methods, we found 
that irradiated HSCs were enlarged compared to control HSCs (Fig. 1A 
and fig. S1B). Our analysis further showed that only a fraction of HSCs 
became enlarged, as judged by a broadening rather than a shift in 
the size distribution (fig. S1C). The size increase of irradiated HSCs 
was, however, not only caused by irradiation arresting HSCs in G2 
phase (18). Enlargement was also observed when specifically analyzing 
G0/1 HSCs (Fig. 1A).
To determine whether large HSC size was associated with 
irradiation-induced senescence, we correlated cell size with senescence- 
associated beta-galactosidase (SA--gal) 2 weeks after either 3- or 
6-Gy irradiation (17). We did not detect high SA--gal activity 
in HSCs obtained from 3-Gyirradiated or control animals (fig. S1D). 
In contrast, SA--galhigh HSCs were readily observed in 6 Gy–irradiated 
animals. Next, we sorted HSCs on the basis of SA--gal activity levels 
and found that SA--galhigh HSCs were larger than SA--gallow HSCs 
from the same animal (fig. S1, E to G). Thus, low doses of irradia-
tion (3 Gy) cause HSC enlargement without detectable induction of 
SA--gal activity, whereas a higher dose (6 Gy) leads to enlarged 
HSCs that harbor high levels of SA--gal activity. These observa-
tions indicate that limited DNA damage enlarges HSCs before in-
ducing a bona fide senescence program and that large HSCs are more 
likely to be senescent.
To determine whether increased HSC size contributes to their 
irradiation-induced dysfunction, we prevented HSC enlargement 
during irradiation. We treated mice with rapamycin (mTOR inhib-
itor) or vehicle for 2 weeks and irradiated them with 3 Gy or left 
the mice untreated (control), followed by a rapamycin or vehicle 
treatment for another 2 weeks. Rapamycin treatment prevented HSCs 
from increasing in size in response to irradiation (3 Gy  +  RAP; 
Fig. 1A and fig. S1B) without changing the cell cycle state of HSCs as 
measured by DNA content and 5-ethynyl-2′-deoxyuridine (EdU) 
incorporation (fig. S1, H and I). Rapamycin treatment neither de-
creased the level of DNA damage after 3-Gy irradiation as evaluated 
by alkaline comet assays (Fig. 1B and fig. S1J) nor altered the differ-
entiation potential of HSCs as demonstrated by blood lineage analysis 
after reconstitution (fig. S1K). We conclude that rapamycin prevents 
HSC enlargement after irradiation.
Having established that rapamycin prevents HSC enlargement 
without affecting the degree of DNA damage, we assessed the effects 
of rapamycin treatment on HSC function. We isolated HSCs from 
donor mice expressing the pan-hematopoietic lineage allele CD45.2 
that were treated with rapamycin or vehicle during 3-Gy irradia-
tion. We then lethally irradiated recipient mice carrying the CD45.1 
allele to eliminate the preexisting blood system. The recipient mice 
were reconstituted with CD45.2 donor HSCs and supporting CD45.1 
BM cells to allow for donor-driven reconstruction of the blood sys-
tem (fitness). Donor HSC fitness was determined by the fraction of 
peripheral CD45.2 white blood cells in CD45.1 recipients over time. 
Rapamycin had a marked effect on the fitness of irradiated HSCs: 
Donor HSCs from mice that were 3 Gy irradiated and received rapamy-
cin treatment exhibited a significantly increased reconstitution po-
tential compared to HSCs from 3 Gy–irradiated mice (Fig. 1C and 
fig. S1L). The degree of chimerism changed over time. The contri-
bution to the blood system of 3 Gy–irradiated HSCs treated with rapa-
mycin increased over the course of the reconstitution, whereas the 
fitness of vehicle-treated 3 Gy–irradiated HSCs decreased (slope analysis; 
Fig. 1C). This observation indicates that HSC proliferation, rather 
than homing to the BM, is affected by rapamycin. We note that rapa-
mycin was not universally radioprotective. The drug failed to confer 
radioprotection at higher radiation doses (5 Gy; fig. S1M) despite 
suppressing SA--gal activity levels (fig. S1D). We conclude that 
rapamycin prevents radiation-induced HSC exhaustion. We inter-
pret this result to suggest that when cellular enlargement is prevented 
by rapamycin during DNA damage, HSCs retain their fitness.
Fig. 1. Cellular enlargement contributes to DNA damage–induced fitness decline in HSCs. (A) Mean volume (fl) of HSCs obtained from vehicle (n = 6), sublethally 
irradiated (3 Gy, n = 4), G0/1 2.8 to 3 Gy (n = 11), rapamycin-treated (RAP, n = 4), and RAP + 3 Gy–treated (n = 7) mice 2 weeks after irradiation (∆ = difference). (B) Measure-
ment of DNA damage using CometChip: percentage tail DNA of HSCs (%) isolated from mice 2 weeks after treatment with vehicle, 3 Gy, RAP, or 3 Gy + RAP 
(n ≥ 166). (C) Reconstitution assay: Donor (CD45.2) mice were pretreated with RAP or vehicle for 2 weeks, sublethally irradiated (3 Gy), and treated with RAP 
(n; donors = 12, recipients = 8) or vehicle (n; donors = 12, recipients = 15) for another 2 weeks before 1000 CD45.2 HSCs were isolated and transplanted into lethally irradiated 
recipient mice. Control donor HSCs were not treated (control, n; donors = 6, recipients = 9) or treated with RAP without irradiation (control, n; donors = 3, recipients = 5). 
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The Cdk4/6 inhibitor palbociclib enlarges HSCs causing their 
decline in reconstitution potential
How does irradiation lead to HSC enlargement? Directly after irra-
diation, HSCs experience DNA damage and arrest in G2 to repair 
this damage (18). This arrest is, however, transient. HSC populations 
return to their preirradiation cell cycle state 2 weeks after sublethal 
irradiation (fig. S1, H and I). Despite the return of HSCs to the G0/1 
state, their size increased (Fig. 1A). In vitro studies with budding 
yeast and primary human cells provide a potential explanation for 
this finding. During cell cycle arrest, mTOR continues to promote 
macromolecule biosynthesis and cells increase in size (11, 12).
To determine whether cell cycle arrest causes HSCs to enlarge, 
we examined HSC size in response to treating animals with the 
Cdk4/6 inhibitor palbociclib (PD), which arrests cells in G1 phase 
(19). Because HSCs rarely divide under physiological conditions (20, 21), 
we injected PD every other day for 120 days (fig. S2A). This treat-
ment regimen increased G0/1 length as judged by cell cycle analysis 
and changes in blood composition of donor animals (fig. S2, B to E). 
Analysis of HSC size after various lengths of PD treatment showed 
that HSCs increased in size in a time-dependent manner (fig. S2A). 
After 85 days of PD treatment, the mean volume of HSCs was 263 fl 
as measured by Coulter counter, which reflects an increase in size 
of 15.5% compared to control HSCs (Fig. 2A). These data indicate 
that delaying cells in G0/1 by PD treatment causes HSC enlargement 
in vivo.
Characterization of PD-enlarged HSCs revealed increased DNA 
damage (Fig. 2B), which was not associated with the production of 
SA--gal activity (fig. S2F). The finding that a PD arrest is associated 
with DNA damage, causal or consequential, afforded us another 
opportunity to assess whether large HSCs that harbor DNA damage 
exhibit decreased reconstitution potential. A previous study showed 
that short-term inhibition of Cdk4/6 (12 hours, trilaciclib) did not 
reduce HSC reconstitution potential (19). Cell size, however, is not 
expected to increase within the treatment time frame of this study. 
Fig. 2. The Cdk4/6 inhibitor PD enlarges HSCs, causing their decline in reconstitution potential. (A) Mean volume (fl) of HSCs isolated from mice treated with vehicle 
(n = 6), Cdk4/6 inhibitor (PD, n = 10), RAP (n = 4), or Cdk4/6 inhibitor + RAP (n = 5) for 85 days (∆ = difference). Same control as in Fig. 1A. (B) DNA damage in CometChip: 
percentage tail DNA of HSCs (%) isolated from mice treated with vehicle, Cdk4/6 inhibitor (PD), RAP, or Cdk4/6 inhibitor + RAP (n ≥ 552). (C) Reconstitution assay: CD45.2 
mice were treated with vehicle (n; donors = 5, recipients = 8), Cdk4/6 inhibitor (PD, n; donors = 5, recipients = 7), RAP (n; donors = 5, recipients = 8), or Cdk4/6 inhibitor + 
RAP (n; donors = 5, recipients = 5) for 85 days before their HSCs were isolated for transplantation into lethally irradiated CD45.1 recipient mice. No drug treatment was 
performed after the reconstitution. Percentage (%) of donor-derived white blood cells in recipient and slope of reconstitution kinetics were determined over time. 
(D) Experimental strategy to determine the role of cell size for HSC fitness: If size determinates fitness, then similarly sized HSCs are expected to exhibit a similar reconstitution 
potential, irrespective of whether HSCs were treated with vehicle or Cdk4/6 inhibitor (PD). (E) Reconstitution assay: 600 M- or XL-sized HSCs of CD45.2 donor mice treated 
with vehicle (n; donors = 6, recipients ≥7) or Cdk4/6 inhibitor (PD, n; donors = 9, recipients M = 12, XL = 9) were transplanted into lethally irradiated recipient mice (CD45.1), 
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We found that prolonged PD treatment enlarged HSCs and impaired 
their reconstitution potential (Fig. 2C and fig. S2G). To determine 
whether the large size of PD-treated HSCs contributed to their 
reduced reconstitution potential, we prevented size increase during 
PD treatment by simultaneously treating animals with rapamycin. 
When treated with PD and rapamycin, HSCs displayed DNA damage 
but they did not increase in size (Fig. 2, A and B). Their reconstitu-
tion potential was preserved (Fig. 2C). Thus, rapamycin prevents 
PD- induced enlargement of HSCs and preserves their fitness.
We hypothesized that if PD treatment indeed decreases fitness 
because it enlarges HSC size, then HSCs of PD-treated animals that 
did not grow to a large size should exhibit a reconstitution potential 
similar to that of untreated animals. In other words, medium (M)–sized 
HSCs from PD-treated mice should exhibit a greater reconstitution 
potential than large (XL)–sized HSCs from PD- or vehicle-treated 
mice (Fig. 2D). We found this to be the case. To obtain M-sized and 
XL-sized HSCs from PD-arrested or vehicle-treated mice, we used 
the forward scatter during cytometric sorting. We isolated the larg-
est 10% of HSCs (XL) and HSCs of a mean size ± 10% (M) (22). Cell 
volume analysis confirmed that we isolated PD- or vehicle-treated 
HSCs of the same absolute size using the M (246 fl) or XL gate 
(305 fl, 24% larger; fig. S2H). M-sized PD-treated HSCs were more 
effective in reconstituting lethally irradiated mice than XL-sized 
PD– or vehicle-treated HSCs (Fig. 2E). These results indicate that 
PD-induced enlargement rather than PD-treatment per se causes 
HSCs to be less fit. We note that M-sized PD-treated HSCs appear 
less fit than vehicle-treated, M-sized HSCs when comparing recon-
stitution kinetics (slope). This difference is however not statistically 
significant. It is nevertheless possible that PD treatment also affects 
HSC potential in a cell size–independent manner. We conclude that 
PD reduces HSC fitness largely by increasing their cell size.
Cellular growth enlarges HSCs and reduces their 
reconstitution potential
Large size contributes to the decreased reconstitution potential of 
HSCs with DNA damage. To determine whether enlargement alone 
decreases HSC fitness in vivo, we analyzed HSCs that were large 
but lacked DNA damage. To create large undamaged HSCs, we 
manipulated mTOR pathway activity. The lack of TSC1 causes con-
stitutive activation of mTOR signaling, which increases cell growth and 
enlarges the size of blood cells (23). Cre-driven excision of TSC1 in 
TSC1fl/fl;R26-creERT2 mice (henceforth TSC1−/−) enlarged HSCs by 
27 to 60% without causing increased DNA damage (Fig. 3, A and B). 
Next, we isolated HSCs from TSC1fl/fl;R26-creERT2 mice and recon-
stituted lethally irradiated recipients (Fig. 3C). We allowed HSCs to 
home to the BM in recipients for 3 days, then induced TSC1 excision 
using tamoxifen, and assessed donor TSC1−/− HSC fitness. TSC1−/− 
HSCs were impaired in repopulating the blood system of recipient 
mice (Fig. 3D). We conclude that constitutive mTOR-driven growth 
enlarges HSCs without causing DNA damage and yet reduces their 
ability to reconstitute lethally irradiated recipients. These data sup-
port the conclusion that increased cell growth enlarges HSCs and 
decreases their fitness.
Consecutive cell divisions cause HSCs to enlarge, which 
drives their exhaustion
We hypothesized that if cellular enlargement contributes to HSC 
dysfunction, then any condition causing loss of stem cell potential 
ought to be accompanied by HSC enlargement. Successive cell divi-
sions cause stem cell exhaustion. With each cell division, HSCs lose 
their cell division potential, such that each daughter cell is less potent 
than its mother (20, 24). We determined whether HSCs enlarge 
during two conditions known to cause higher levels of cell divisions 
in vivo: pregnancy (25) and transplantation into irradiated mice (4). 
G0/1 HSCs of breeding females and HSCs obtained after transplan-
tation were enlarged (Fig. 4, A, C, and D). As in response to radia-
tion, not all HSCs enlarged during serial transplantation, as judged 
by a broadening of the size distribution (fig. S3A). This was not due 
to changes in cell cycle distribution. Eighty days after transplantation 
(the time cell size was analyzed), HSCs had returned to the same cell 
cycle profile as before transplantation (fig. S3, B and C). In secondary 
transplants, donor HSCs did not increase further in size (Fig. 4D), 
suggesting that an upper size threshold exists for HSCs.
The two methods of increasing the rate of HSC division also 
caused a decrease in reconstitution potential (Fig. 4B and fig. S3D). 
This decreased fitness was not due to transplanting actively proliferating 
Fig. 3. mTOR hyperactivation enlarge HSCs, contributing to their fitness decline. (A) Mean volume (fl) of TSC1+/+ (n = 6), TSC1−/− (n = 5), and G0/1 TSC1−/− HSCs (n = 3) 
60 days after vehicle or tamoxifen treatment. Same control as in Fig. 1A. (B) CometChip assay to measure DNA damage: Percentage tail DNA of HSCs (%) from TSC1+/+ 
(n = 769) or TSC1−/− (n = 838) mice. (C) A total of 800 HSCs from TSC1fl/fl;R26-creERT2 mice were transplanted into lethally irradiated recipient mice and were allowed to 
home to the bone. The recipients were then treated with vehicle or tamoxifen to induce TSC1 excision 3 and 14 days after transplantation. (D) Reconstitution assay 
described in (C): Percentage (%) of TSC1+/+ (n; donors = 7, recipients = 11) and TSC1−/− (n; donors = 7, recipients = 7) donor HSC–derived white blood cells in recipients and 
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HSCs (26) because we only transplanted HSCs in G0/1. We conclude 
that, similar to budding yeast and primary mammalian cell in vitro 
(9, 13), successive divisions of HSCs are accompanied by an increase 
in HSC size and decrease in fitness.
The reconstitution experiment afforded us the opportunity to 
determine whether cell division–driven enlargement promotes HSC 
exhaustion. We conducted transplantation experiments, in which 
recipients received prolonged rapamycin treatment to prevent HSC 
enlargement during the many divisions needed to reconstitute the 
hematopoietic compartment (Fig. 4C). This experimental regime 
indeed prevented donor HSCs from enlarging (Fig. 4D). Preventing 
enlargement of donor HSCs in the host via rapamycin treatment 
improved their fitness during the reconstitution (Fig. 4E). We con-
clude that successive divisions cause HSCs to enlarge, which reduces 
their stem cell potential.
To directly test whether HSCs that divided more often are larger, 
we took advantage of the inducible histone 2B (H2B)–green fluo-
rescent protein (GFP) mouse model (24, 27) to simultaneously ana-
lyze division history and cell size. We induced H2B-GFP expression 
(pulse) and then transplanted GFPhigh HSCs into lethally irradiated 
recipients to induce HSC division (chase; Fig. 4F). Four weeks after 
the transplantation, HSCs from recipients treated with vehicle or 
rapamycin (chase-vehicle, RAP) lost their GFP intensity, indicating 
that the divisions needed to rebuild the recipients’ blood system 
diluted H2B-GFP in HSCs (Fig. 4G). In comparison, HSCs main-
tained high GFP intensity in donor animals 4 weeks after the 
pulse (chase-control). HSCs from vehicle-treated recipient mice 
were enlarged, while rapamycin prevented this increase in size 
(Fig. 4H). We conclude that HSCs increase in size after successive 
division.
Fig. 4. High cell division frequency enlarges HSCs, contributing to their fitness decline. (A) Mean volume (fl) of G0/1 HSCs from age-matched virgin (n = 3) and breed-
ing (n = 5) mice. (B) Reconstitution assay: A total of 600 G0/1 HSCs from age-matched virgin (n; donors = 6, recipients = 9) or breeding (n; donors = 5, recipients = 6) donor 
(CD45.2) mice were transplanted into lethally irradiated recipients. Donor-derived white blood cells (%) in recipients and slope of reconstitution kinetics are shown. 
(C) Transplantation experiment. (D and E) Following transplantation, recipients were treated with RAP or vehicle. HSC volume was analyzed before transplantation and 
80 days after the 1° and 2° transplantation. BM from 1° transplant was used for 2° transplant. (D) Mean volume (fl) of donor HSCs before transplantation (n = 9) and after 
recipient treatment with vehicle (n = 9), vehicle G0/1 (n = 3), or RAP (n = 8) treatment during 1° or 2° transplantation (n = 4). (E) Reconstitution assay: Donor HSCs were 
transplanted into lethally irradiated recipients, which were then treated with vehicle (n; donors = 10, recipients = 11) or RAP (n; donors = 10, recipients = 14). Donor- 
derived white blood cells (%) in recipients and slope of reconstitution kinetics were determined. (F) Experimental overview: rtTa;tetO-H2B-GFP mice (“before pulse”) were 
treated to induce H2B-GFP (“pulse”). Afterward, HSCs were transplanted into recipients, which were treated with vehicle (“chase-vehicle”) or RAP (“chase-RAP”). Control 
HSCs from donor rtTa;tetO-H2B-GFP animals were analyzed after the pulse (“chase-control”). (G) Experiment as in (F): GFP intensity (a.u., arbitrary unit) of G0/1 HSCs from 
before pulse (n = 3), pulse (n = 3), chase-control (n = 3), chase-vehicle (n = 5), and chase-RAP (n = 3) mice. (H) Experiment as in (F): Mean volume (fl) of G0/1 HSCs from before 
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Why does an increased cell division frequency cause HSC en-
largement? Stochastic damage can occur during every cell division 
(28, 29). When cells are damaged, cell cycle checkpoints are activat-
ed to facilitate repair (18, 30). During this arrest, mTOR continues 
to promote macromolecule biosynthesis driving cell growth and 
enlargement (11, 12, 16). Hence, the more divisions a cell under-
goes, the more likely it encounters damage that causes cell cycle 
arrest and therefore enlargement. Our data indicate that, in HSCs 
too, successive divisions cause enlargement, which, in turn, leads 
to HSC dysfunction. We note that this hypothesis also explains why 
only a fraction of HSCs enlarge during serial transplantations.
Naturally large HSCs display decreased 
reconstitution potential
Our data show that DNA damage, increased cellular growth, prolif-
eration challenge, or artificially increasing cell size decreases HSC fitness. 
To determine the broader physiological relevance of this observation, 
we assessed the fitness of naturally large HSCs. We isolated the 
smallest 10% of HSCs (XS), the largest 10% of HSCs (XL), and HSCs 
of a mean size ± 10% (M; Fig. 5A) from young wild-type (WT) mice 
by flow cytometry using forward scatter. Cell volume analysis by Coulter 
counter confirmed that this method can differentiate HSCs on the 
basis of their size when size differences are large (Fig. 5, B and C). 
XS HSCs (mean = 209 fl) were 14% smaller than M HSCs (mean = 
240 fl), which were 30% smaller than XL HSCs (mean = 312 fl).
We next investigated why XL HSCs are large. During cell divi-
sion, cells increase in size to maintain constant volumes of the two 
daughter cells. To determine whether XL HSCs were large because 
they were in the process of dividing, we analyzed their DNA con-
tent. While most differently sized HSCs were in G0, XL HSCs were 
less in G1 and more often in S phase or mitosis (S/G2-M; fig. S4, A 
to C). As XL HSCs are not polyploid (31), these data indicate that 
the XL HSC population is composed of large G0/1 HSCs and HSCs 
that are larger because they are in S/G2-M.
Fig. 5. Naturally large HSCs are impaired in reconstituting the hematopoietic compartment. (A) Size distribution of HSCs as determined by forward scatter (FSC-A). 
Gates used to isolate small (XS), medium (M), and large (XL) HSCs are indicated. SSC-A, side scatter. (B) HSCs (%) per volume (fl) isolated using the XS, M, or XL gates shown in 
(A). Gaussian fit was used to determine mean cell volume. Dotted line marks the mean of M-sized HSCs. (C) Mean volume (fl) of HSCs isolated using the XS (n = 6), M (n = 8), XL 
(n = 6), or G0/1 XL (n = 3) gates (∆ = difference). (D) CometChip assay to measure DNA damage: Percentage tail DNA of XS-, M- and XL-, G0/1 XL- and S/G2-M XL-sized HSCs 
(n > 323 cells measured per condition). (E) Schematic of reconstitution experiments in (F) to (H): A total of 600 differently sized donor-derived HSCs were transplanted into 
lethally irradiated recipients. (F) Reconstitution assay: Donor-derived (CD45.2) white blood cells (%) in recipients after transplantation of XS (n; donors = 5, recipients = 6), 
M (n; donors = 5, recipients = 6), or XL (n; donors = 5, recipients n = 6) G0/1 Hoechst-labeled donor HSCs. Slope of reconstitution kinetics is shown. (G) Reconstitution assay: 
Donor-derived (CD45.2) white blood cells (%) in recipients after transplantation of XS HSCs (n = 6) or XL donor G0/1 CD34− HSCs (n = 6). (H) Reconstitution assay: Donor-derived 
(CD45.2) white blood cells (%) in recipients after transplantation of XS/M (n; donors = 5, recipients = 5) or XL G0 donor HSCs (n; donors = 5, recipients = 5) from Ki67-RFP mice. 
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To determine whether naturally large G0/1 HSCs harbor DNA 
damage, we performed an alkaline CometChip assay. This analysis 
revealed that G0/1 XL HSC nuclei displayed a higher percentage of 
tail DNA compared to XS- and M-sized HSCs and higher levels of 
H2AX phosphorylation (Fig. 5D and fig. S4D). We conclude that 
WT mice harbor large G0/1 HSCs, which have more DNA damage 
compared to small WT HSCs.
To assess the fitness of naturally XL HSCs in vivo, we isolated 
XS, M, and XL HSCs and reconstituted lethally irradiated recipient 
mice (Fig. 5E). Because HSCs in S/G2-M are impaired in providing 
long-term multilineage reconstitution (26, 32), we specifically iso-
lated G0/1 HSCs using a DNA stain. The reconstitution potential 
differed with HSC size. XS- and M-sized G0/1 HSCs effectively con-
tributed to the peripheral blood of recipient mice, whereas XL G0/1 
HSCs exhibited a significantly reduced reconstitution potential 
(Fig. 5F and fig. S4, E and F). We observed that same result when we 
isolated G0/1 CD34-negative XS-, M-, and XL-sized HSCs or HSCs 
of different sizes in the G0 cell cycle state (Fig. 5, G and H). DNA 
staining can alter HSCs fitness, but reconstitutions without staining 
the DNA of HSCs revealed similar results (fig. S4G). XS HSCs en-
larged during reconstitutions, while G0/1 XL HSCs remained large 
by the end of the reconstitution experiment (Fig. 5I). This indicates 
that XL HSCs do not shrink back to their original size during the 
divisions necessary to rebuild the recipients’ blood system.
In summary, we have examined six different experimentally in-
duced or physiological conditions, under which HSCs exhaustion 
occurs: irradiation-induced DNA damage, Cdk4/6 inhibition, hy-
peractivation of mTOR, high division rate during transplantation, 
repeated pregnancy, and naturally large HSCs. We observe that HSCs 
enlarge under all these conditions. In all experimental settings, in 
which this could be investigated, preventing HSC enlargement with 
rapamycin preserved HSC fitness.
Large HSCs exhibit decreased proliferation potential 
and changed metabolism
Why are large HSCs less fit than small HSCs? Large size could affect 
(i) proliferation potential, (ii) stem cell identity and differentiation 
potential, (iii) the metabolic state of HSCs, and/or (iv) protein syn-
thesis capacity. We chose naturally large and PD-enlarged HSCs to 
test these possibilities.
(i) Proliferation potential
The observation that PD-enlarged and XL-donor HSCs contribute 
less to the blood lineages of recipient animals over time (reconstitu-
tion slopes) indicated that cell size affects HSC proliferation. The 
analysis of HSC proliferation in vitro confirmed this conclusion. 
We found that PD-enlarged HSCs formed fewer colonies than con-
trol HSCs (fig. S5A). Rapamycin treatment partially restored colony 
formation of PD-treated HSCs. A decrease in proliferation was also 
observed in naturally large HSCs, although the effect was less notable. 
We also investigated whether large size affected homing of HSCs to 
the BM niche, which is essential for hematopoiesis. We injected XL- or 
PD-enlarged donor HSCs into CD45.1 recipient mice and exam-
ined the fraction of CD45.2 donor cells in the BM 21 hours thereaf-
ter. This analysis suggested that HSC size did not affect homing 
potential (fig. S5B). We conclude that cellular enlargement inter-
feres with the ability of HSCs to proliferate.
(ii) Stem cell identity and differentiation potential
To determine whether cell size affects HSC identity or their ability 
to differentiate into the various hematopoietic lineages, we first con-
ducted a comparison of gene expression profiles between differently 
sized HSCs using gene set enrichment analysis (GSEA). This analysis 
revealed that the expression pattern of several Gene Ontology (GO) 
gene sets changed in G0/1 XL HSCs compared to smaller control 
HSCs (M and XS). To identify transcriptional changes in XL HSCs 
that underlie the decline in fitness in vivo, we focused our analysis 
on GO sets that specifically changed in XL HSCs relative to XS and 
M HSCs but not between XS and M HSCs. A total of 2.4% of all GO 
gene sets passed this filter (table S1). Using a cutoff that required 
that >20% of GO gene sets associated with a given biological process 
to be differentially regulated between XL HSCs versus XS and M HSCs, 
we identified the following pathways (fig. S5C): DNA damage (21% of 
associated GO gene sets were differentially regulated in XL- versus 
XS/M-sized HSCs), proteasome (30%), excision/mismatch repair 
(50%), RNA processing (32%), transfer RNA modification (23%), 
Fig. 6. Large HSCs exhibit altered metabolism. (A) Mitochondrial concentration [intensity (a.u.)/volume (fl) in XS, M, and XL HSCs (n = 4)]. (B) ROS concentration dichlo-
rodihydrofluorescein diacetate (DCF-DA) intensity (a.u.)/volume (fl) in XS, M, and XL HSCs (n = 4). (C) Heatmap of expression levels of mitochondrial genes in differently 
sized G0/1 HSCs (n = 2). (D) Metabolites were analyzed using liquid chromatography–tandem mass spectrometry: Volcano plots of metabolite changes induced by in G0/1 
XL HSCs compared to G0/1 XS HSCs. Red/blue circles show metabolites significantly depressed/elevated, and symbols in black show unchanged metabolites (n = 7). NAD+, 
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and nucleases (27%). The up-regulation of genes involved in DNA 
damage response and repair was biologically relevant. Naturally 
large HSCs harbored more DNA damage than smaller control 
HSCs (Fig. 5D). In the comparison between PD-enlarged HSCs to 
control HSCs, only 0.3% of the GO gene sets passed the functional 
filter and no enrichment for particular biological processes was ob-
served (table S1).
To specifically determine whether size affected the self-renewal 
or differentiation ability of HSCs, we used published lists of genes 
related to HSC identity and differentiation (table S2) (33–40) and 
analyzed whether their expression changed in XL- and PD-enlarged 
HSCs. We found that only a few genes rose to the level of significant 
differential expression (table S3). A principle components analysis 
confirmed that size had little or no effect on the expression of gene 
sets associated with stem cell identity and differentiation (fig. S5D). 
To evaluate the biological relevance of these results, we used func-
tional assays to assess differentiation potential of large-sized HSCs 
in vitro and in vivo. The ability to form cells of the myeloid, B cell, 
and T cell lineages did not significantly differ between mice recon-
stituted with differently sized HSCs (fig. S5E). Differentiation was 
also not significantly affected in vitro. The types of colonies formed 
by HSCs in methylcellulose cultures were similar between HSCs of 
different sizes (fig. S5F). Last, the concentration of stem cell surface 
markers was similar between differently sized HSCs (fig. S5G). We 
conclude that cell size does not significantly affect stem cell identity 
or differentiation potential of HSCs.
(iii) Metabolic state
Prior studies suggested that stem cells can enter a metabolically ac-
tivated state, which is characterized by an increase in cell size, high 
mitochondrial activity, high adenosine 5′-triphosphate (ATP) lev-
els, and up-regulation of the interferon- (IFN-) response (41, 42). 
We determined whether HSC enlargement could reflect HSCs in 
such an activated state. In contrast to activated stem cells, mito-
chondrial function was decreased in large G0/1 HSCs as judged by 
Fig. 7. Reducing cellular size restores HSC fitness. (A) RB+/+;R26-cre or RBfl/+;R26-cre mice were DNA-damaged (2.8 to 3 Gy) to measure HSC volume (B) and treated with 
tamoxifen reducing HSC size. Afterward, HSC volume was measured (B) and 700 G0/1 donor HSCs were transplanted into lethally irradiated recipients to measure their 
fitness (C) and volume (D) in recipients. (B) Mean volume (fl) of G0/1 HSCs from RB+/+;R26-cre or RBfl/+;R26-cre mice after 2.8 to 3 Gy (n = 4) and tamoxifen treatment (n = 5 
to 11) as described in (A). Day −1 = before irradiation. Same control and 2.8- to 3-Gy sample as in Fig. 1A. (C) Reconstitution assay: White blood cells (%) derived from donor 
RB+/+;R26-cre (n; donors = 6, recipients = 11) or RBfl/+;R26-cre (n; donors = 5, recipients = 5) 2.8- to 3-Gy G0/1 HSCs that were treated before transplantation with tamoxifen 
as described in (A). Slope of reconstitution kinetics was determined. (D) Mean volume (fl) of recipient-derived donor RB+/+;R26-cre (n = 4) or RBfl/+;R26-cre (n = 3) 2.8- to 3-Gy 
G0/1 HSCs that were treated before transplantation with tamoxifen as described in (A). (E) Experiment schematic: A total of 600 XS- or XL-sized G0/1 HSCs from RB+/+;R26-cre 
or RBfl/+;R26-cre mice were transplanted into lethally irradiated recipients. Afterward, recipients were treated with tamoxifen to reduce HSC size and to measure fitness 
(F) and volume (G) of donor G0/1 HSCs in recipients. (F) Reconstitution assay: Percentage (%) of donor-derived white blood cells in recipients and slope of reconstitution as 
described in (E) (n; donors = 4, recipients XL-RB fl/+ = 6, XS-RB fl/+ = 5, XL-WT = 9, XS-WT = 5). Red arrows indicate tamoxifen treatment. (G) Mean volume (fl) of donor G0/1 
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mitochondrial concentration (Fig. 6A), reactive oxygen species 
(ROS) concentration (Fig. 6B), and transcript concentration of 
mitochondrial genes (fig. S6C), while mitochondrial fission (43) was 
not affected (fig. S6A). Liquid chromatography–mass spectrometry 
(LC-MS) revealed that G0/1 XL HSCs harbored significantly lower 
levels of ATP than XS-sized HSCs (Fig. 6D). Last, we found that 40% 
of GO gene sets associated with the IFN response were lower in 
XL HSCs compared to smaller HSCs but not significantly different 
between smaller HSCs (XS and M) using a relaxed functional filter 
(q value = 0.5; fig. S6B). Thus, when evaluating the concentration of 
energy-related factors, our data suggest that large HSCs do not ex-
hibit characteristics of an activated state.
(iv) Protein synthesis capacity
Enlarged cultured primary human cells experience decreased pro-
tein synthesis rates and ribosome loss that leads to cytoplasm dilu-
tion (12, 44). To assess protein synthesis capacity in naturally large 
HSCs, we measured nucleolar size as this often correlates with ribo-
somal RNA synthesis and ribosome biogenesis (45, 46). Nucleolar 
size scaled with HSC size (fig. S6, C and D), suggesting that ribosome 
biogenesis does not decline in large HSCs. Consistent with this 
conclusion, cell density, to which ribosomes are a contributor (44), 
was not affected in large HSCs either (fig. S6E). Furthermore, 
mTOR activity (phosphorylated S6 levels) and protein synthesis 
in vivo (47) were not affected by cell size (fig. S6, F and G). Last, we 
measured the nucleus:cytoplasm ratio (C/V) of differently sized 
HSCs. We found that larger HSCs tended to display a lower C/V 
(fig. S6H). In summary, our characterization of naturally large and 
PD-enlarged HSCs indicates that large size primarily interferes 
with the ability of HSCs to proliferate and to maintain a functional 
metabolic state.
Large size decreases the colony-forming potential 
of intestinal stem cells
Does cell size also affect the proliferation potential of other adult 
stem cell types? To address this question, we used Lgr5-GFP knock-in 
mice to isolate intestinal stem cells (ISCs), which can be distin-
guished from transient amplifying cells by a twofold or higher in-
tensity of Lgr5-GFP (fig. S7, A and B). We isolated the smallest 15% 
of ISCs, the largest 15%, and the mean-sized population ± 15% us-
ing the forward scatter as a measure of cell size (fig. S7C). Cell vol-
ume measurements confirmed that this method distinguished ISCs 
by their size (fig. S7D). Furthermore, like naturally large HSCs, XL 
ISCs harbored more DNA damage than smaller ones (fig. S7E). 
They also shared other characteristics with XL HSCs. They exhibited 
a reduced ability to form intestinal organoids (fig. S7F), a colony 
formation assay for ISCs. Among all the differently sized ISCs, XL 
ISCs displayed the highest intensity of Lgr5-GFP (fig. S7G), sug-
gesting that the colony-forming defect observed in XL ISCs was not 
due to them having differentiated into Lgr5low progenitors. We con-
clude that, like in HSCs, DNA damage is associated with an increase 
in ISC size and a decrease in colony-forming potential.
Reducing the size of large HSCs restores their 
reconstitution potential
Our results indicate that preventing HSC enlargement with rapa-
mycin during DNA damage or during high frequency of cell divi-
sion preserves HSC fitness. To robustly test whether HSC size and 
fitness are causally connected, we modulated HSC size by means 
other than rapamycin treatment. We shortened G1.
Inactivation of the S-phase entry inhibitor Rb accelerates pro-
gression through G1 and reduces cell size (48). We hypothesized 
that reducing the size of large HSCs by reducing Rb levels improves 
HSC fitness. To reduce Rb levels in HSCs, we used mice that were 
heterozygous for an excisable RB allele (RBfl/+;R26-creERT2). We first 
sublethally irradiated mice and allowed HSCs to enlarge for 7 days 
(Fig. 7, A and B). We then excised one RB allele by administering 
tamoxifen for another 7 days. Loss of one copy of RB indeed led to 
decreased cell size after irradiation (Fig. 7B). To determine whether 
reducing the size of previously enlarged HSCs improved their re-
constitution potential, we transplanted these irradiated HSCs into 
recipients (Fig. 7C). This analysis revealed that the lack of one RB 
copy affected the fitness of previously irradiated, large HSCs: Irradi-
ated RB+/− HSCs built 15% of the blood cells of reconstituted 
animals, whereas irradiated RB+/+ HSCs contributed only 5%, which is 
consistent with our hypothesis that DNA-damaged and RB-deficient 
HSCs divide more (fig. S8A) (49). During the reconstitution, these 
irradiated RB+/− HSCs were smaller in size than irradiated RB+/+ 
HSCs (Fig. 7D). We conclude that reducing cell size improves the 
reconstitution potential of irradiated HSCs.
Does reducing the size of naturally large HSCs also restore their 
reconstitution potential? To address this, we transplanted XL-sized 
RBfl/+;R26-creERT2 HSCs. Fourteen days after transplantation, we 
treated animals with tamoxifen to excise one copy of the RB gene 
(Fig. 7E). This not only reduced the size of XL HSCs but also signifi-
cantly increased the ability of XL HSCs to build the hematopoietic 
compartment of recipients. RB−/+ HSCs formed 47% of blood cells 
in recipients, whereas RB+/+ HSCs contributed only 23% (Fig. 7, 
F and G). Tamoxifen itself had no significant effect on HSC fitness 
(fig. S8B). Consistent with increased reconstitution potential, RB- 
excised XL HSCs more readily entered the cell cycle (fig. S8C). RB 
removal did not improve HSC fitness of small or control HSCs 
(Fig. 7F) (50), indicating that lack of Rb does not improve HSC 
function per se but restores fitness of large HSCs by reducing their 
size. We conclude that the reduced fitness of naturally large HSCs 
can be improved by reducing their size. Our data demonstrate that 
HSC size is an important determinant of their in vivo fitness.
HSC enlargement contributes to their functional decline 
during aging
Like many other stem cells, the function of HSCs declines with or-
ganismal age with HSCs losing their ability to regenerate the hema-
topoietic system (51). Large HSCs share many of the characteristics 
of cellular aging: loss of stem cell potential, loss of proliferative abilities, 
up-regulated expression of genes associated with aging (fig. S9A), 
increased DNA damage, and enlarged nucleoli (42, 52). On the ba-
sis of these observations, we hypothesized that HSCs enlarge in vivo 
as mice age. We analyzed HSC size in a mouse strain that experiences 
HSC decline at a younger age (D2) and in the BL/6 strain, in which 
HSC decline occurs later in life. HSCs were larger in old D2 (32 weeks), 
BL/6 middle-aged (56 to 65 weeks), and BL/6 old (86 to 102 weeks) 
animals compared to younger mice (8 weeks; Fig. 8, A and B). This 
size difference was neither due to changes in cell cycle distribution 
(fig. S9, B and C) nor associated with changes in SA--gal activity 
(fig. S9D). As in response to irradiation, only a fraction of HSCs 
became enlarged, as judged by a broadening of the size distribution 
(D2 and BL/6; fig. S9E). One interpretation of this observation is 
that this change in cell size distribution is due to stochastic cellular 
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while most other HSCs stay quiescent or do not experience damage 
during cell division (53).
To determine whether cellular enlargement contributed to the 
fitness decline of HSCs from aged mice, we prevented HSC enlarge-
ment during organismal aging. We treated young D2 and BL/6 mice 
from week 8 with rapamycin and found that aging-induced HSC 
enlargement was prevented (Fig. 8, A and B). These small-old D2 HSCs 
proliferated more and formed more colonies in vitro compared to 
large-old D2 HSCs (Fig. 8C and fig. S9F). Rapamycin also preserved 
the reconstitution potential of old BL/6 HSCs. HSCs obtained from 
middle-aged or old BL/6 mice that were kept small by rapamycin 
treatment (Fig. 8B) were more effective in reconstituting lethally 
irradiated recipients than old-enlarged HSCs (Fig. 8, D and E, and 
fig. S9G). Rapamycin had no effect on the fitness of HSC from 
young mice (Figs. 1C and 2C) or on in vivo differentiation (fig. 
S9H). In secondary transplantations, this result remained as a trend 
(fig. S9I). These data indicate that HSC enlargement contributes to 
the fitness decline of HSCs during aging. However, rapamycin was 
not able to reverse HSC enlargement and age-induced loss of stem 
cell fitness. When we treated old animals (week 77 onward) for 2 to 
3 months with rapamycin, we did not observe a reduction in HSC 
size (fig. S9J) or recovery in HSC reconstitution potential (fig. S9K). 
This observation further indicates that rapamycin does not improve 
HSC fitness per se but that its long-term effects on cell growth and 
size mediate preservation of HSC fitness. Our data suggest that HSC 
enlargement contributes to their functional decline during aging.
Last, we observed a similar relationship between cell size and 
aging in human HSCs (Lin−, CD34+, CD90+, CD38−, CD45RA−, 
Fig. 8. Enlargement of HSCs contributes to fitness decline during aging. (A) Mice were treated with vehicle or RAP during aging (from week 8 onward), and HSCs were 
analyzed at 32 weeks (D2 mice) for volume (B) and in vitro colony formation (C) or at 56 to 65 weeks (middle aged, BL/6) and 86 to 102 (old, BL/6) weeks for reconstitution 
capacity (D and E). (B) Mean volume (fl) of HSCs from 7-week-old (young, n = 4), 32-week-old (old, n = 9), or old + RAP (n = 10) early-aging D2 mice and from 5- to 9-week-
old (young, n = 9), 56- to 65-week (middle-aged, n = 10), middle-aged G0/1 (n = 8), middle-aged + RAP (n = 7), 86- to 102-week-old (old, n = 8), or old + RAP (n = 4) BL/6 mice. 
RAP treatment started at 8 weeks. Same WT BL/6 control as in Fig. 4D. (C) Colony-forming efficiency in vitro: HSCs from D2 mice treated with vehicle or rapamycin during 
aging were analyzed for colony-forming potential in vitro (%, n = 5). (D) Reconstitution assay: A total of 800 donor-derived HSCs from middle-aged (56 to 65 weeks) BL/6 
mice treated with vehicle (n; donors = 12, recipients = 16) or rapamycin (n; donors = 12, recipients = 14) during their life were transplanted into lethally irradiated recipi-
ents. Percentage (%) of donor-derived white blood cells in recipients and slope of the reconstitution kinetics were measured over time. (E) Reconstitution assay: A total of 
1000 donor-derived G0/1 HSCs from old (86 to 102 weeks) BL/6 mice treated with vehicle (n; donors = 6, recipients = 6) or rapamycin (n; donors = 4, recipients = 4) during 













Lengefeld et al., Sci. Adv. 7, eabk0271 (2021)     12 November 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
11 of 16
and ±CD49f+). HSCs were larger in 51- to 62-year-old individuals 
compared to 21- to 25-year-old individuals (Fig. 9, A and B). 
Old-large human HSCs also exhibited a decreased ability to form 
colonies in vitro and to form multicellular lineages upon differenti-
ation (Fig. 9, C and D). We conclude that HSC enlargement during 
aging contributes to their functional decline in mice and humans.
DISCUSSION
Large cell size causes a decline in stem cell function
Stem cells are innately small in size. Here, we show that size main-
tenance is important for the function of HCSs and probably also for 
other stem cell types. Conditions known to reduce stem cell 
potential—DNA damage and successive cell proliferation—cause 
an increase in HSC size. Two lines of evidence indicate that cell size 
affects HSC function: (i) Preventing HSC enlargement during 
insults such as DNA damage, aging, and consecutive divisions pro-
tects HSCs from losing their stem cell potential and (ii) reducing the 
size of large HSCs improves their fitness.
Our data provide an explanation for why HSCs and ISCs are 
small. While this has been largely unexplored for other stem cell 
types, there are some reports showing that cell types displaying 
characteristics of stem cells are small in size (54–56). Thus, it is likely 
that mechanisms connecting cellular size with function are con-
served in other stem cell types as well.
A key question regarding our findings is whether large HSCs 
are truly stem cells that have lost their stem cell potential or whether 
enlargement reflects a partially differentiated cellular state, in which 
multipotency had become restricted. We find that naturally and ar-
tificially enlarged HSCs are indistinguishable from smaller HSCs in 
their ability to home to the BM niche and to differentiate into the 
various hematopoietic lineages in vitro and in vivo. The perhaps 
most compelling evidence that large HSCs are true stem cells is the 
observation that reducing the size of naturally large or irradiated 
HSCs improved their reconstitution potential.
It is important to note that, in response to DNA damage, prolifer-
ation challenge, and aging, not all HSCs increase in size, but the size 
distribution of HSCs widens. This indicates that only a subpopulation 
of HSCs enlarges during these challenges. We propose that this 
subpopulation is composed of HSCs that experienced DNA damage 
during irradiation and have divided more often during prolifera-
tion challenge and aging. A history of divisions increases the like-
lihood of HSCs to have experienced DNA damage that caused cell 
cycle arrest and hence cellular enlargement. Most other HSCs are 
quiescent. Their size will not be affected by insults such as DNA 
damage because mTOR activity is low during quiescence (57).
Our analysis of naturally large HSCs also revealed that they do 
not return to a smaller cell size when induced to proliferate during 
reconstitution assays. At first glance, this result appears unanticipated. 
Several studies suggest that within their physiological size range, 
cells enter the cell cycle when they have reached a cell type–specific 
cell size, known as the critical size. When cells enlarge during cell 
cycle arrests, the subsequent G1 is shortened and two smaller 
daughter cells are born (58–64). We hypothesize that this return to 
a smaller cell size only occurs when enlargement during cell cycle 
arrest does not exceed the critical size. When HSCs enlarge during 
prolonged cell cycle arrests beyond their critical cell size, restoration 
of the physiological size is no longer possible. In other words, they 
cannot shrink back to their natural size. This is consistent with studies 
observing a size increase over successive divisions (9, 13, 14, 65). 
Our data also indicate that HSCs do not grow in size indefinitely. 
Perhaps HSCs have an upper size limit, beyond which they die or 
faithful size homeostasis occurs at a different size set point. However, 
it is clear from earlier studies that once cells become exceedingly large 
as occurs in cultured cells during senescence, multiple cellular pro-
cesses, foremost cell division, fail (12, 16). Our results suggest that the 
size window, in which HSCs function physiologically, is small. In-
creasing HSC size by as little as 5 to 15% leads to a decline in fitness.
Causes of fitness decline in large HSCs
Our results indicate that in vitro proliferation capacity of HSCs is 
affected by large size. Given that cell proliferation is crucial for HSCs 
to rebuild the hematopoietic system of lethally irradiated mice, it is 
likely that reduced proliferative capacity is, at least in part, respon-
sible for reduced fitness of large HSCs in vivo. We note the option 
that an underlying cause of cell size, rather than cell size itself, is 
Fig. 9. HSCs are larger in aged humans. (A and B) Mean volume (fl) of human HSCs (Lin−, CD34+, CD90+, CD38−, CD45RA− with and without CD49f+) from young (21 to 
25 years, n ≥ 5) or old (51 to 62 years, n ≥ 5) individuals. (C) Colony-forming efficiency in vitro: Human HSCs from young (21 to 25 years) or old (51 to 62 years) individuals 
were plated onto methylcellulose, and the percentage of HSCs forming a colony was quantified after 21 days (n = 3). (D) Differentiation assay in vitro: Percentages of human 
GEMM, GM, or single lineages (G, M, and E) colonies per plate were counted after 21 days (n = 3). CFU, colony-forming units; BFU, burst-forming unit; GEMM, = granulocyte, 
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responsible for reduced HSC fitness. Our previous work indicates 
that it is not the physical size of large cells that causes their reduced 
fitness, but rather the ensuing change in ratio of DNA to cytoplasm. 
Cellular enlargement in the absence of a corresponding increase in 
DNA content leads to a decrease in DNA:cytoplasm ratio. The con-
centration of unstable proteins decreases when this occurs in bud-
ding yeast (12). In naturally large HSCs, protein synthesis capacity 
and cell density of the whole cell are not changed, yet their fitness 
is decreased. HSCs have a very small cytoplasmic volume compared 
to their nuclear volume and, with enlargement, their DNA:cytoplasm 
ratio slightly decreases. As a result, loss of unstable proteins specifi-
cally in the cytoplasm might contribute to some degree to impaired 
fitness upon enlargement. This is consistent with the observation 
that protein synthesis rates in HSCs must be tightly controlled (66). 
The observation that rapamycin treatment suppresses the fitness 
decline of HSCs during DNA damage further raises the possibility 
that mTOR-regulated processes besides cell growth, such as auto-
phagy, or mitochondrial and lysosome function (2) influence HSC 
fitness during aging. Last, while HSCs are able to scale mitochon-
dria upon HSC activation (42), our findings indicate that once HSCs 
exceedingly enlarge, they become depleted of mitochondria and 
metabolites like ATP. This might be an important clue for how en-
largement causes dysfunction.
A model for damage- and aging-induced loss of stem 
cell function
We have known since the 1960s that senescent mammalian cells are 
exceedingly large (9, 10). Similarly, aged yeast cells were first de-
scribed to be large in the 1950s (13). These observations prompted 
us to investigate whether large cells harbor characteristics of senes-
cence in vivo. We show here that DNA damage and aging lead to an 
increase in HSC size and that large size causes a decrease in HSC 
function. Young yeast and cultured primary human cells that are 
large also exhibit many of the phenotypes observed in senescent cells. 
On the basis of these observations, we propose that as stem cells 
divide and age, they experience DNA damage incurred during DNA 
replication or caused by telomere shortening (fig. S9L) (28, 29). This 
DNA damage triggers cell cycle checkpoints, and division transient-
ly ceases to repair this DNA damage (18, 30). During these transient 
arrests, cell growth continues and HSCs increase in size (11, 12). 
This enlargement then causes proliferation defects. In other words, 
it is not the division history itself that drives stem cell exhaustion, 
but the cellular enlargement resulting from past cellular damage in-
curred during cell divisions. Hence, this mechanism contributing to 
cell aging would be similar to replicative senescence observed in 
cultured human cells. We further propose that as large HSCs ac-
cumulate in the HSC population with age, smaller HSCs engage 
in more self-renewing divisions to compensate for the loss of func-
tional stem cells (53), which might explain the observed upper limit of 
HSC size during aging. This model also provides an explanation for why 
very old mice harbor more cycling HSCs compared to young ones.
Our findings may have implications for rejuvenation therapies 
to improve stem cell function during aging. Rapamycin treatment 
has been reported to lengthen the life span of mice and improves 
the function of aged HSCs (67, 68). Our data indicate that rapamy-
cin prevents the enlargement of HSCs and thereby protects them 
and potentially other stem cells from aging. However, rapamycin 
does not restore HSC function once they are large. We predict that 
compounds that revert cellular enlargement and hence reduce the 
size of already enlarged stem cells warrant further exploration as 
potential antiaging therapies.
MATERIALS AND METHODS
Please find detailed description of materials and methods in the 
Supplementary Materials.
Mice
All work was performed in accordance with the Massachusetts In-
stitute of Technology (MIT) Institutional Animal Care Facility and 
with guidelines at MIT (Institutional Animal Care and use committee) 
(protocol numbers 0715-073-18 and 0718-053-21). Mice were pur-
chased from Jax Laboratories or as indicated: B6.SJL-PtprcaPepcb/
BoyJ (#002014), C57BL/6 J (#000664), DBA/2 J (D2) (JAX #000671, 
Charles River Laboratories #026), Lgr5-EGFP-IRES-CreERT2 
(#008875), Ki67RFP knock-in (#029802) Rosa26CreERT2;TSC1fl/fl 
(#005680 and #008463), Rosa26CreERT2;RBfl/+ (#026563 and #008463), 
and R26-rtTA tetO-H2B-GFP (#005104 and #006965).
HSC isolation and measurements
Murine BM–derived HSCs were isolated as described previously (69). 
The following antibodies from were used: Rat monoclonal phyco-
erythrin [PE (phycoerythrin)]/Cy7 anti-mouse CD150, BioLegend, 
catalog no. 115913 [RRID (Research Resource Identifiers): AB_439796]; 
Rat monoclonal PE anti-mouse CD150, BioLegend, catalog no. 115904 
(RRID: AB_313683); Armenian hamster monoclonal BV421 anti- 
mouse CD48, BioLegend, catalog no. 103427; (RRID: AB_10895922); 
Armenian hamster monoclonal Allophycocyanin (APC)/Cy7 anti- 
mouse CD48, BioLegend, catalog no. 103431 (RRID: AB_2561462); 
Rat monoclonal PE/Cy7 anti-mouse Ly-6A/E, BioLegend, catalog no. 
108114 (RRID: AB_493596); Rat monoclonal APC anti-mouse 
CD117, BioLegend, catalog no. 105812 (RRID: AB_313221); Rat 
monoclonal PE anti-mouse CD150, BD Biosciences, catalog no. 
562651 (RRID: AB_2737705); Rat monoclonal fluorescein isothio-
cyanate (FITC) anti-mouse Ly-6A/E, BD Biosciences, catalog no. 
562058 (RRID: AB_10898185); Rat monoclonal PE/Cy7 anti-mouse 
Ly-6A/E, BioLegend, catalog no. 108114 (RRID: AB_493596); 
Rat monoclonal PE/Cy5 anti-mouse CD150, BioLegend, catalog no. 
115911 (RRID: AB_493599); Armenian hamster monoclonal FITC 
anti-mouse CD48, BioLegend, catalog no. 103404 (RRID: AB_313019); 
and Rat monoclonal APC anti-mouse CD117, BD Biosciences, 
catalog no. 561074 (RRID: AB_10563203).
Human BM samples were purchased from AllCells, whose guide-
lines follow strictly the need for informed consent. HSCs were puri-
fied as described previously (70). The following antibodies were used: 
Mouse APC anti-human Lineage Cocktail (CD3, CD14, CD16, CD19, 
CD20, and CD56), BioLegend, catalog no. 348803; Mouse mono-
clonal FITC anti-human CD90, BD Biosciences, catalog no. 561969 
(RRID: AB_10895382); Rat monoclonal PE-Cy5 anti-human CD49f, 
BD Biosciences, catalog no. 551129 (RRID: AB_394062); Mouse 
monoclonal PE-Cy7 anti-human CD45RA, BD Biosciences, catalog 
no. 560675 (RRID: AB_1727498); and Mouse monoclonal PE anti- 
human CD38, BD Biosciences, catalog no. 342371 (RRID: AB_400453).
Cell cycle stage analysis
A total of 106 BM cells/ml in prewarmed Iscove's modified Dulbecco's 
medium (IMDM) with 2% fetal bovine serum and Hoechst-33342 
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between G0 and G1 HSCs, we took advantage of transgenic Ki67-
RFP mice and analyzed HSCs that were stained with Hoechst-33342 
as described above using flow cytometry. Vybrant DyeCycle Violet 
Stain (Thermo Fisher Scientific, #V35003) was used at 5 M per 
106 cells/ml incubating cells at room temperature for 30 min. For 
in vivo proliferation studies, 1.25 mg of EdU was injected intraper-
itoneally into mice 24  hours before sacrifice. EdU incorporation 
into the DNA of HSCs was evaluated according to the manufacturer’s 
instructions with the Click-iT EdU Alexa Fluor 488 Imaging Kit.
HSC volume measurements
Size of HSCs was determined using a Multisizer-3 Coulter Counter 
(Beckman Coulter) or as indicated. The forward scatter (FSC-A) 
was used to isolate HSCs of a specific size (XS, M, and XL).
Reconstitution and homing assays
Reconstitution and homing assays were performed as described 
previously (69) using live HSCs (C57BL/6 J and CD45.2) combined 
with 420,000 B6.SJL (CD45.1) supporting white blood cells per mouse. 
Peripheral blood from recipient mice was depleted of red blood 
cells using Ammonium-Chloride-Potassium (ACK) buffer then 
incubated with the following: Mouse monoclonal PE anti-mouse 
CD45.1, BioLegend, catalog no. 110708 (RRID: AB_313497); Mouse 
monoclonal FITC anti-mouse CD45.2, BioLegend, catalog no. 
109806 (RRID: AB_313443); Rat monoclonal BV421 anti-mouse 
Ly-6G and Ly-6C, BD Biosciences, catalog no. 562709 (RRID: 
AB_2737736); Rat monoclonal BV421 anti-mouse CD11b, BD 
Biosciences, catalog no. 562605; (RRID: AB_11152949); Rat mono-
clonal BV421 anti-mouse CD45R/B220, BD Biosciences, catalog 
no. 562922 (RRID: AB_2737894); Hamster monoclonal BV421 
anti-mouse CD3e, BD Biosciences, catalog no. 562600 (RRID: 
AB_11153670).
Homing assays were performed as reconstitution experiments, 
except that 6000 to 8000 donor HSCs were injected. The percentages 
of donor HSCs in the bone in relation to recipient BM cells were 
determined 21 hours after reconstitution.
RNA isolation
HSCs were sorted into 750 l of TRIzol LS. To extract RNA, 200 l 
of chloroform was added to the sample and briefly vortexed at 
medium speed. The sample was centrifuged at 12,000g for 15 min 
at 4°C. Four hundred microliters of the aqueous phase was re-
moved and put into 1400 l of RLT buffer (Qiagen) with 14 l of 
-mercaptoethanol and mixed vigorously. One milliliter of 100% etha-
nol was added to each sample, mixed by pipetting, and then loaded 
onto RNeasy Micro Kit (Qiagen) columns. The manufacturer’s di-
rections were followed from the RW1 wash step, and the sample was 
eluted into 14 l of diethyl pyrocarbonate water.
For RNA sequencing (RNA-seq) analysis, samples were analyzed 
for RNA integrity using a Femto Analyzer. Then, the Clontech v4 
Low-Input RNA Kit was used for the PolyA library prep. RNA-seq 
data were aligned to the mm10 mouse genome assembly and the 
ensemble version 88 annotation with STAR version 2.5.3a and gene 
expression was summarized with RSEM version 1.3.0 (71).
RNA-seq analysis
Expression data were analyzed using two different data sets: (i) all 
human GO gene sets MSigDb version 7.1 and (ii) mouse gene cate-
gories of HSCs based on previous studies (33–40).
Differentially expressed genes were defined as those having an 
absolute log2 fold change greater than 1 and a false discovery 
rate–adjusted P value of less than 0.05 (q value). DESeq2 and edgeR 
version 3.4.4 programs were used to perform principle components 
analysis. Data parsing and clustering were performed using TIBCO 
Spotfire Analyst 7.6.1. Mouse genes were mapped to human ortho-
logs using Preranked. GSEA analysis was performed using javaGSEA 
version 2.3.0. Preranked GSEA (version 4.0.3) was run using the 
DESeq2 Wald statistic as ranking metric and human gene symbols 
with the MSigDB of the C5 GO gene sets.
In vitro cultivation of murine and human HSCs
Murine or human HSCs were resuspended in complete MethoCult 
GF M3434 medium or MethoCult H4435 Enriched (STEMCELL 
Technologies), grown at 37°C in a 5% CO2 chamber, was monitored 
until colonies were visible (7 and 21 days, respectively). Number of 
colonies and colony type were quantified manually.
Measurements of single-cell density and volume using 
a suspended microchannel resonator
HSCs were isolated as detailed above and cultured ex vivo for 2 days 
in expansion medium (StemSpam SFEM, #09600 supplemented 
with cytokines). Single-cell density and volume measurements were 
carried out using the suspended microchannel resonator, as detailed 
previously (72, 73).
Intestinal crypt isolation and organoid formation 
assay of ISCs
Isolation of ISCs was previously reported (74). ISCs were sorted by 
flow cytometry into crypt culture medium, a modified form of 
medium as described previously (74). Isolated ISCs and Paneth cells 
were then mixed (1:1 ratio, 2000 cells each) and seeded onto Matrigel 
(Corning, 356231 growth factor reduced) containing 1 M JAG-1 
protein (AnaSpec, AS-61298). Organoid-forming capacity of the 
sorted ISCs was quantified after 3 to 5 days of culture. Each frequency 
was quantified by n > 100 cells per view and n = 3 views per sample.
Drug and irradiation treatments
PD (30.4 mg/kg body weight), rapamycin (6.4 mg/kg body weight), 
or vehicle was intraperitoneally injected every 48 hours for the indi-
cated treatment time. Mice were treated from week 8 with rapamycin 
every 3 days until week 102. The Cre-recombinase was activated via 
tamoxifen intraperitoneal injections of 2 mg/100 l per dose.
Fluorescence assays
For immunofluorescence analyses, slides were primed with 0.1% 
polylysine and HSCs incubated for 1 hour. HSCs were fixed, perme-
abilized, and blocked using 10% donkey serum. Cells were incu-
bated with primary antibody: anti–phospho-S6 ribosomal protein 
(Ser240/244) rabbit monoclonal antibody (Cell Signaling Technology, 
catalog no. 5364; RRID:AB_10694233), anti–P-Ser139 H2XA 
(1:100; Cell Signaling Technology, catalog no. 2577; RRID: AB_211801), 
or anti-Drp1 (1:100; Abcam, catalog no. ab56788, RRID:AB_941306). 
The secondary antibody solution (1:500; goat anti-rabbit Alexa 
Fluor 488, Cell Signaling Technology, 4412S and 1:500 goat anti- 
mouse Alexa Fluor 488, Invitrogen, A-10680) was added for 1 hour. 
Coverslips were mounted with ProLong Gold Antifade Reagent 
(Invitrogen, Molecular Probes). Images were acquired using a 
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(GE Healthcare Bio-Sciences) equipped with a CoolSNAP HQ2 
camera (Roper), 250-W xenon lamps, and SoftWoRx software 
(Applied Precision). Deconvolution was performed using Soft-
WoRx software with default settings. For the imaging and quantifi-
cation of fibrillarin-stained nucleolus, immunofluorescent images 
were acquired using a laser-scanning confocal microscope (Leica 
TCS SP8-X) using the Lightning mode with a 100× oil immersion/1.46 
numerical aperture objective using a 1.28 optical zoom. Leica 
Applications Suite X 3.5.5.19976 software was used for image ac-
quisition. The nucleus:cytoplasmic ratio was calculated like this: 
N/C = nucleus area/(cell area – nucleus area). To detect mitochon-
drial mass and ROS, we used MitoTracker Green or CM-H2DCFDA 
as described (75, 76). To detect senescent HSCs, we used C12FDG 
(Setareh Biotech, #7188) as described previously (77). Protein 
synthesis was measured as described in detail before (47).
Comet assay
The CometChip polydimethylsiloxane molds were fabricated using 
the protocols described in (78). The CometChip gel was incubated 
in alkaline lysis stock (2.5 M NaCl, 100 mM Na2EDTA, 10 mM tris, 
and 1% Triton X-100) to allow for DNA unwinding and then 
incubated in formamidopyrimidine DNA glycosylase (M0240S, 
New England Biolabs). Next, electrophoresis was performed in the 
alkaline electrophoresis buffer. The CometChip was neutralized in 
neutralization buffer (0.4 M tris-HCl at pH 7.5) and stained with 
SYBR Gold (S11494, Invitrogen). Images were captured with a Nikon 
80i upright microscope and analyzed using the Guicometanalyzer, a 
custom software written in MATLAB (The MathWorks).
Metabolite measurements in HSCs using LC-MS
Methods for the isolation of cells for metabolomics were previously 
described (79). The LC-MS method involved hydrophilic interaction 
chromatography coupled to a Q Exactive PLUS mass spectrometer 
(Thermo Fisher Scientific). The LC separation was performed on an 
XBridge BEH Amide column (150 mm by 3 2.1 mm, 2.5-mm particle 
size, Waters, Milford, MA). Solvent A is 95%:5% H2O:acetonitrile 
with 20 mM ammonium bicarbonate, and solvent B is acetonitrile. 
The gradient was 0 min, 85% B; 2 min, 85% B; 3 min, 80% B; 5 min, 
80% B; 6 min, 75% B; 7 min, 75% B; 8 min, 70% B; 9 min, 70% B; 
10 min, 50% B; 12 min, 50% B; 13 min, 25% B; 16 min, 25% B; 18 min, 
0% B; 23 min, 0% B; 24 min, 85% B; and 30 min, 85% B. Other LC 
parameters are as follows: flow rate, 150 ml/min; column tempera-
ture, 25°C; injection volume, 10 l; and autosampler temperature, 
5°C. The mass spectrometer was operated in both negative and pos-
itive ion modes for the detection of metabolites. Other MS param-
eters are as follows: resolution, 140,000 at mass/charge ratio (m/z) 
200, automatic gain control target, 3e6; maximum injection time, 
30 ms; and scan range, m/z 75 to 1000. Raw LC-MS data were con-
verted to mzXML format using the command line “msconvert” utility. 
Data were analyzed via the El-Maven software.
Quantification, statistical analysis, and data and materials 
availability statement
Guidelines for quantification, statistical analysis, and data availabil-
ity have been followed. Each experiment was repeated with three mice 
or as indicated (biological replicates). Representative experiments 
are shown only if the experiment was repeated three times and the 
results of each one supported the same conclusion. SDs of the mean 
of three independent data points are shown in graphs or as indicated. 
Asterisks indicate P values: ****P < 0.0001, ***P < 0.001, **P < 0.01, 
and *P < 0.05; NS, not significant. For all panels, statistical significance 
was calculated using unpaired t test to compare two samples, one-
way analysis of variance (ANOVA), multiple comparison, and Tukey’s 
post hoc test to compare multiple (three or more) samples or other-
wise specified. Values were only excluded if the most extreme value 
in the dataset was a significant outlier from the rest (P  <  0.05) 
according to Grubbs’ test. No statistical method was used to prede-
termine sample size. The RNA-seq data are available from the Gene 
Expression Omnibus under accession number GSE154335. All other 
data supporting the findings of the study are available from the cor-
responding author upon request.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abk0271
View/request a protocol for this paper from Bio-protocol.
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